Healthy volunteers needed to test new drug forms in 7-Week study
NCT ID NCT07607483
First seen Jun 06, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This study tests 3 different forms (a tablet and 2 types of capsule) of the experimental drug LY4065967 in 36 healthy adults. The goal is to measure how much and how quickly each form gets into the bloodstream, and to check for side effects. Participants will stay in a research unit for 3 separate 3-night stays over about 7 weeks. This is a phase 1 trial with no direct treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
Contact Phone: •••-•••-••••
Contact
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.